Grufity logoGrufity logo

Abiomed Inc Stock Research

ABMD

Delayed

ABMD Stock Price

ABMD RSI Chart

ABMD Valuation

Market Cap

17.2B

Price/Earnings (Trailing)

64.52

Price/Sales (Trailing)

16.02

EV/EBITDA

46.18

Price/Free Cashflow

79.23

ABMD Price/Sales (Trailing)

ABMD Profitability

EBT Margin

31.76%

Return on Equity

17.32%

Return on Assets

15.72%

Free Cashflow Yield

1.26%

ABMD Fundamentals

ABMD Revenue

Revenue (TTM)

1.1B

Revenue Y/Y

7.16%

Revenue Q/Q

-4.05%

ABMD Earnings

Earnings (TTM)

266.8M

Earnings Y/Y

86.35%

Earnings Q/Q

94.55%

Price Action

Last 7 days

0.2%

Last 30 days

1.2%

Last 90 days

54.1%

Trailing 12 Months

14.7%

ABMD Financial Health

Current Ratio

7.93

ABMD Investor Care

Buy Backs (1Y)

0.58%

Diluted EPS (TTM)

5.83

Peers (Alternatives to Abiomed)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
104.1B
18.4B
2.26% 8.00%
44.16
5.64
7.84% 18.25%
84.2B
6.2B
-4.47% -13.27%
63.66
13.53
8.97% -22.43%
69.1B
12.7B
0.59% 12.45%
99.06
5.45
6.68% -32.95%
67.4B
19.0B
-5.16% -6.78%
41.86
3.55
-0.43% -8.78%
49.8B
5.4B
2.41% -25.12%
32.74
9.26
2.86% 1.25%
MID-CAP
7.2T
489.7M
9.34% 31.15%
82.2K
16.8K
106.51% 2464.23%
10.2B
847.1M
-3.64% 34.52%
-5.1K
12.05
13.32% -137.89%
5.2B
1.0B
-11.64% -20.31%
30.19
5.09
6.76% 24.45%
3.5B
410.9M
4.51% -3.13%
-29.82
8.43
27.29% -14.60%
2.7B
801.2M
1.13% -58.87%
-28.25
3.34
14.00% -707.69%
SMALL-CAP
1.7B
138.6M
-15.68% 29.18%
-30.43
12.07
36.62% -10.44%
1.6B
350.9M
10.38% 49.06%
-10.84
4.7
44.26% -5.42%
1.3B
820.0M
-8.35% -12.22%
25.89
1.59
10.13% 701.59%
828.4M
239.8M
0.30% 1.49%
-21.88
3.45
-4.74% -31.15%

Financials for Abiomed

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue1.7%1,0741,0561,0321,003974
  S&GA Expenses3.2%452438423414393
  R&D Expenses0.6%167166163152144
Costs and Expenses2.5%820800891865828
EBITDA23.9%369298219217-
EBITDA Margin21.9%0.34*0.28*0.21*0.22*-
Earnings Before Taxes26.5%341270191189212
EBT Margin24.4%0.32*0.26*0.18*0.19*-
Net Income22.6%267218137133149
Net Income Margin20.6%0.25*0.21*0.13*0.13*-
Free Cahsflow-17.3%217263250246-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-0.4%1,6971,7041,6731,5931,530
  Current Assets0.2%1,0631,060976885871
    Cash Equivalents1.0%182180133144242
  Inventory7.2%10295.0094.0090.0086.00
  Net PPE-1.7%195198202197197
  Goodwill-2.5%73.0075.0077.0077.0078.00
Liabilities-6.4%157167170160145
  Current Liabilities-4.8%134141138127114
Shareholder's Equity0.2%1,5401,5361,5031,4331,385
  Retained Earnings10.4%1,1251,019965904858
  Additional Paid-In Capital2.2%905885870853840
Accumulated Depreciation3.9%10610299.0093.00-
Shares Outstanding-0.9%45.0046.0046.0046.0045.00
Float-14,400----
Cashflow (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-15.8%251298285293282
  Share Based Compensation0.5%54.0053.0053.0054.0055.00
Cashflow From Investing38.2%-162-263-380-324-250
Cashflow From Financing-626.0%-135-18.67-2.20-1.586.00
  Buy Backs772.2%25329.000.00--

Risks for ABMD

What is the probability of a big loss on ABMD?

80%


Probability that Abiomed stock will be more than 20% underwater in next one year

58.1%


Probability that Abiomed stock will be more than 30% underwater in next one year.

31.5%


Probability that Abiomed stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ABMD drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Abiomed was unfortunately bought at previous high price.

Drawdowns

Returns for ABMD

Cumulative Returns on ABMD

39.5%


10-Year Cumulative Returns

23.2%


7-Year Cumulative Returns

14.7%


5-Year Cumulative Returns

32.7%


3-Year Cumulative Returns

What are the long-term rolling returns for ABMD?

FIve years rolling returns for Abiomed.

Annualized Returns

Which funds bought or sold ABMD recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-15
B. Riley Wealth Advisors, Inc.
sold off
-100
-217,000
-
-%
2023-03-10
BAILLIE GIFFORD & CO
reduced
-99.92
-889,365,000
1,136,580
-%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
sold off
-100
-1,981,000
-
-%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-98.99
-22,791,000
361,000
-%
2023-03-03
TIAA, FSB
sold off
-100
-250,000
-
-%
2023-03-01
WHITENER CAPITAL MANAGEMENT, INC.
sold off
-100
-415,000
-
-%
2023-02-28
Voya Investment Management LLC
sold off
-100
-6,959,000
-
-%
2023-02-24
National Pension Service
sold off
-100
-19,252,300
-
-%
2023-02-24
NATIXIS
sold off
-100
-2,940,000
-
-%
2023-02-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
reduced
-89.99
-8,166,000
1,501,000
0.02%

1–10 of 49

Latest Funds Activity

Are funds buying ABMD calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own ABMD
No. of Funds

Abiomed News

StockNews.com

JNJ: 3 Powerhouse Stocks to Buy in 2023.

StockNews.com,
7 days ago

StockNews.com

Sarasota Herald-Tribune

StockNews.com

GuruFocus.com

Baillie Gifford Slashes Meta,.

GuruFocus.com,
51 days ago

StockNews.com

Johnson & Johnson

Schedule 13G FIlings of Abiomed

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jan 06, 2023
baillie gifford & co
0.01%
2,991
SC 13G/A
Dec 29, 2022
millennium management llc
0.0%
0
SC 13G
Feb 09, 2022
vanguard group inc
10.64%
4,842,984
SC 13G/A
Feb 04, 2022
wellington management group llp
5.41%
2,461,221
SC 13G
Jan 18, 2022
baillie gifford & co
8.44%
3,839,980
SC 13G/A
Jan 10, 2022
blackrock inc.
10.1%
4,592,566
SC 13G/A
Feb 16, 2021
sands capital management, llc
3.27%
1,479,909
SC 13G
Feb 10, 2021
vanguard group inc
10.63%
4,801,759
SC 13G/A
Feb 10, 2021
renaissance technologies llc
4.41%
1,993,800
SC 13G/A
Jan 29, 2021
blackrock inc.
9.1%
4,127,359
SC 13G/A

ABMD Fair Value

Abiomed fair value in different scenarios

The table shows the Fair Value estimates for Abiomed for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

80.22

-

99.36

-

131.90

-

255.51

-

350.32

-
Current Inflation

74.18

-

90.52

-

117.84

-

223.06

-

303.31

-
Very High Inflation

66.71

-

79.82

-

101.20

-

185.39

-

249.11

-

Historical Abiomed Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Abiomed

View All Filings
Date Filed Form Type Document
Jan 06, 2023
SC 13G/A
Major Ownership Report
Jan 03, 2023
15-12G
15-12G
Dec 29, 2022
SC 13G
Major Ownership Report
Dec 27, 2022
4
Insider Trading
Dec 27, 2022
4
Insider Trading
Dec 27, 2022
4
Insider Trading
Dec 27, 2022
4
Insider Trading
Dec 27, 2022
4
Insider Trading
Dec 27, 2022
4
Insider Trading
Dec 27, 2022
4
Insider Trading

Latest Insider Trading transactions for ABMD

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-02-17
Rolle Myron L
sold (taxes)
-36,447
325
-112
-
2022-02-17
SUTTER MARTIN P
sold
-1,258,850
314
-4,000
-
2022-02-16
SUTTER MARTIN P
sold
-617,322
308
-2,000
-
2022-02-16
Weber David M
sold
-2,437,500
325
-7,500
chief operating officer
2022-02-15
SUTTER MARTIN P
sold
-607,301
303
-2,000
-
2022-02-09
Weber David M
sold
-965,311
310
-3,112
chief operating officer
2022-02-09
Weber David M
acquired
67,063
21.55
3,112
chief operating officer
2022-02-08
Weber David M
acquired
159,750
21.55
7,413
chief operating officer
2022-02-08
Weber David M
sold
-2,245,420
302
-7,413
chief operating officer
2022-02-07
Weber David M
acquired
6,465
21.55
300
chief operating officer

1–10 of 50

Michael R. Minogue
2000
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the Automated Impella Controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; and Impella BTR, a percutaneous micro heart pump with integrated motors and sensors. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

ABMD Income Statement

2022-09-30
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]    
Revenue$ 265,921$ 248,142$ 543,070$ 500,727
Costs and expenses:    
Cost of revenue48,88043,886101,50689,074
Research and development42,08941,04182,56678,749
Selling, general and administrative116,958102,779234,954206,263
Acquired in-process research and development000115,490
Costs and Expenses, Total207,927187,706419,026489,576
Other (loss) income:    
Income from operations57,99460,436124,04411,151
Interest and other income, net80,7096,83584,48146,770
Income before income taxes138,70367,271208,52557,921
Income tax provision32,57010,31847,83827,493
Net income$ 106,133$ 56,953$ 160,687$ 30,428
Net income per share - basic$ 2.34$ 1.25$ 3.53$ 0.67
Weighted average shares outstanding - basic45,37245,43745,47545,374
Net income per share - diluted$ 2.32$ 1.24$ 3.51$ 0.66
Weighted average shares outstanding - diluted45,71145,89345,81245,857

ABMD Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2022
Mar. 31, 2022
Current assets:  
Cash and cash equivalents$ 182,335$ 132,818
Short-term marketable securities638,037625,789
Accounts receivable, net94,47590,608
Inventories, net102,23793,981
Prepaid expenses and other current assets45,71433,277
Total current assets1,062,798976,473
Long-term marketable securities116,871220,089
Property and equipment, net195,157202,490
Goodwill72,96076,786
Other intangibles, net36,83339,518
Deferred tax assets18,88110,552
Other assets193,044147,485
Total assets1,696,5441,673,393
Current liabilities:  
Accounts payable35,07035,346
Accrued expenses69,43472,629
Deferred revenue25,96226,362
Other current liabilities3,5944,120
Total current liabilities134,060138,457
Other long-term liabilities7,0139,319
Contingent consideration14,99521,510
Deferred tax liabilities689781
Total liabilities156,757170,067
Commitments and contingencies (Note 16)
Stockholders' equity:  
Class B Preferred Stock, $.01 par value Authorized - 1,000,000 shares; Issued and outstanding - none
Common stock, $.01 par value 100,000 shares authorized; 48,418 and 48,258 shares issued as of September 31, 2022 and March 31, 2022, respectively 45,172 and 45,545 shares outstanding as of September 30, 2022 and March 31, 2022, respectively452455
Additional paid in capital904,755870,074
Retained earnings1,125,199964,512
Treasury stock at cost - 3,246 and 2,713 shares as of September 31, 2022 and March 31, 2022, respectively(443,974)(304,555)
Accumulated other comprehensive loss(46,645)(27,160)
Total stockholders' equity1,539,7871,503,326
Total liabilities and stockholders' equity$ 1,696,544$ 1,673,393